EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH

View source ↗

Summary

The EMA has authorised Rubraca (rucaparib camsylate) in the EU for ovarian neoplasms. The marketing authorisation holder is pharmaand GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• RUBRACA (RUCAPARIB)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms. MAH: pharmaand GmbH. Decision date: 27/11/2025